Antibody to reduce brain inflammation and injury after hemorrhagic stroke
減少腦炎症和損傷後的抗體 出血性中風
CA mAb protects brain from inflammatory damage and improves behavior outcomes, IV injected 2-3 hours post stroke. CA mAbs modulate microglia/macrophages polarization toward M2-like (anti-inflammation and repairing) phenotypes
CA mAb 保護大腦免受炎症損傷並改善行為結果，在中風後 2-3 小時靜脈注射。
CA mAb 調節小膠質細胞/巨噬細胞向 M2 樣（抗炎和修復）表型的極化
Targeted indication
Reduce brain injury and improve behavior outcomes after stroke.
2-3 hours-delayed IV injection of Ab post hemorrhagic stroke.
Status
Monoclonal Abs available; Animal mouse models
Key features
- No effective therapeutic drugs for hemorrhagic stroke
- Delayed IV injection, modulate macrophage/microglia polarization from M1 to M2.
- Much less mAb required (1/10 to 1/30 of regular dose). Safe, less ADCC
Market
Therapy for inflammatory related brain and systemic diseases, including psoriasis, brain and other systemic inflammatory related diseases.
Market for Ab drugs to inhibit inflammation: more than US$40 billion/year.
No effective therapeutic agents are available to suppress brain inflammation, such as in stroke, brain trauma and sepsis-induced brain encephalopathy (SAE).
Modulation of macrophage polarization from pro-inflammatory (M1-like) toward anti-inflammatory (M2-like) phenotypes to curb inflammation has become an important approach clinically, including brain diseases, while the effect remains unsatisfactory.
CA mAb-modified macrophages will migrate into brain and tissues to suppress local inflammation which circumvents the drawback of Ab drugs that cannot get through the blood brain barrier.
Less Ab required may reduce side effects such as ADCC
MODE OF ACTION
EXPERIMENTAL RESULTS
CA mAbs attenuate TNF-α and IL-6 expression in bone marrow-derived macrophages post-LPS induction
ICV or 3 hour-delayed IV injection of CA Ab (1 mg/kg) reduces brain injury and improves behavior outcomes after hemorrhagic stroke.
IV injection of CA mAb (1 mg/kg) reduces brain injury after ICH.
Much less mAb required (1 mg/kg, compared with 10 to 30 mg/kg in other mouse study), less ADCC (Ab-dependent cellular cytotoxicity)
Ab will not bind to non-immune cells: less side-effects.
Four mAbs constructed and sequenced. Two of them have been tested with therapeutic efficacy to reduce injury and improve behavior outcomes.
INTELLECTUAL PROPERTY
BUSINESS OPPORTUNITY
Licensing and/or Collaboration, Sponsored Research
CONTACT
service@biip-dcc.org